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We appreciate the opportunity to respond to the thoughtful
comments submitted by Dr. Lemaire [1] about our article
titled “Serum neutrophil gelatinase-associated lipocalin as a
marker of renal function in children with chronic kidney
disease” in Pediatric Nephrology [2]. After careful reas-
sessment of the data, we stand by the results and
conclusions reported in our article.
Dr. Lemaire states that our work “is more suited for
hypothesis generation.” Indeed, we concluded that “the
presentstudysuggests serum neutrophil gelatinase-associated
lipocalin (NGAL) as a candidate for inclusion in a panel of
biomarkers.” We stated important limitations of the study
[cross-sectional design, small sample size, applicable only to
young subjects with chronic kidney disease (CKD)], which
also indicate the preliminary nature of the study and in no
way makes this study conclusive.
Despite limitations of the statistical analysis, related
primarily to the small sample size, the difference in
relationship between NGAL, cystatin C, and estimated
glomerular filtration rate (eGFR) at low levels of GFR
persisted even after artificial manipulation of the data (i.e.
removalofadatapointforNGAL)performedbyDr.Lemaire.
Using the actualdataset,our analysisresultedina decreaseof
R
2 value for GFR–NGAL from 0.38 to 0.26 and not to 0.20,
as reported in Dr. Lemaire’sl e t t e r[ 1]. The R
2 of 0.26 still
represents a significant improvement over the cystatin C–
GFR (R
2=0.08) or eGFR–GFR (R
2=0.12) relationships. We
also feel that there is no justification to arbitrarily consider
one of the NGAL data points as an outlier, as suggested in
Dr. Lemaire’sl e t t e r[ 1].
In Dr. Lemaire’s letter, the clustering of points in the
graph of eGFR and GFR speaks only to these two variables,
not to any other pair of variables. The fact that there is a
negative correlation in this group, rather than being
artifactual, may be due to the fact that eGFR does not
work so well for a certain percentage of the patients in this
subgroup analysis. A close examination of this “subgraph”
shows a number of points fitting very nicely on the original
regression line and a number of other points drifting out to
the right of the line. We cannot discern whether there may
be something different about these subjects compared with
those that fit on the line so well. But why were there no
points to the left of the regression line? Perhaps the GFR–
eGFR relationship breaks down at this low level of GFR for
some patients, depending on the underlying disease
processes. In any case, we are not ready to concede that
the negative correlation seen is artifactual in this case. We
do concede that the correlations produced at a GFR <30
will provide limited information, as this only contains 20%
of the range of GFRs in the study and therefore truncates
this distribution. But this limitation was induced by using a
widely accepted cutoff (GFR <30 ml/min per 1.73 m
2). In
any case, the correlation analyses, and specifically the
subgroup analyses, were performed, as we stated in the
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tween studied biomarkers and measured GFR.” Our
conclusions are not based on the subgroups analyses but
on the results of the regression residual and receiver
operating characteristics analyses. The subgroup analyses
were presented only to confirm that the correlations seen in
the whole group also held for subgroups, and there is no
inconsistency at the low end of the GFR distribution.
The results, regardless of the R
2 value, still suggest that
NGAL outperforms other markers of kidney function in our
study. Does this statistical finding make NGAL a useful
GFR surrogate? Definitely not, and in this respect, we agree
with Dr. Lemaire. As we indicated in the article, larger
confirmative studies are necessary to evaluate the role of
NGAL and other potential biomarkers of kidney function in
children with CKD. Further, as we suggested in the
manuscript, the true value of NGAL may be confirmatory
of progressive decline in kidney function, as it appears to
perform especially well in the moderate range of reduced
GFR.
MonitoringCKDactivity requiresbiomarkersthat provide
clinicians with quick, noninvasive, and specific measure-
ments that correlate with kidney pathophysiology. Current
biomarkers of CKD and its progression, serum creatinine and
urine protein, have serious limitations in serving these goals
[3]. Remarkably, much of the controversy surrounding the
early diagnosis of acute and chronic kidney disease is being
solved by the adaptive response of the stressed kidney itself
[4]. The application of innovative technologies has begun to
identify novel biomarkers that reflect tissue pathology and
predict disease progression prior to the development of
abnormalities in traditional biomarkers [5]. NGAL holds
promise as a method for monitoring CKD progression, and
it has been gratifying to witness the recent literature
providing further support to this notion [3].
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